Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations
- PMID: 30767072
- PMCID: PMC6475635
- DOI: 10.1007/s00424-019-02259-2
Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations
Abstract
Several lines of evidence suggest that the primary effect of hypertrophic cardiomyopathy mutations in human β-cardiac myosin is hypercontractility of the heart, which leads to subsequent hypertrophy, fibrosis, and myofilament disarray. Here, I describe three perspectives on the molecular basis of this hypercontractility. The first is that hypercontractility results from changes in the fundamental parameters of the actin-activated β-cardiac myosin chemo-mechanical ATPase cycle. The second considers that hypercontractility results from an increase in the number of functionally accessible heads in the sarcomere for interaction with actin. The final and third perspective is that load dependence of contractility is affected by cardiomyopathy mutations and small-molecule effectors in a manner that changes the power output of cardiac contraction. Experimental approaches associated with each perspective are described along with concepts of therapeutic approaches that could prove valuable in treating hypertrophic cardiomyopathy.
Keywords: Hypertrophic cardiomyopathy; Interacting heads motif; Load; Super-relaxed state; β-Cardiac myosin.
Conflict of interest statement
J.A.S. is a cofounder of MyoKardia, a biotechnology company developing small molecules that target the sarcomere for the treatment of inherited cardiomyopathies, and of Cytokinetics and is a member of their scientific advisory boards.
Figures






Similar articles
-
Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state.Proc Natl Acad Sci U S A. 2021 Jun 15;118(24):e2025030118. doi: 10.1073/pnas.2025030118. Proc Natl Acad Sci U S A. 2021. PMID: 34117120 Free PMC article.
-
The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin.Sci Adv. 2020 Apr 3;6(14):eaax0069. doi: 10.1126/sciadv.aax0069. eCollection 2020 Apr. Sci Adv. 2020. PMID: 32284968 Free PMC article.
-
Early-Onset Hypertrophic Cardiomyopathy Mutations Significantly Increase the Velocity, Force, and Actin-Activated ATPase Activity of Human β-Cardiac Myosin.Cell Rep. 2016 Dec 13;17(11):2857-2864. doi: 10.1016/j.celrep.2016.11.040. Cell Rep. 2016. PMID: 27974200 Free PMC article.
-
Reassessing the unifying hypothesis for hypercontractility caused by myosin mutations in hypertrophic cardiomyopathy.EMBO J. 2024 Oct;43(19):4139-4155. doi: 10.1038/s44318-024-00199-x. Epub 2024 Aug 27. EMBO J. 2024. PMID: 39192034 Free PMC article. Review.
-
Altered force generation and cell-to-cell contractile imbalance in hypertrophic cardiomyopathy.Pflugers Arch. 2019 May;471(5):719-733. doi: 10.1007/s00424-019-02260-9. Epub 2019 Feb 11. Pflugers Arch. 2019. PMID: 30740621 Free PMC article. Review.
Cited by
-
Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors.Cardiovasc Res. 2024 Mar 14;120(3):301-317. doi: 10.1093/cvr/cvae004. Cardiovasc Res. 2024. PMID: 38240646 Free PMC article.
-
Left Ventricular Hypertrophy: Etiology-Based Therapeutic Options.Cardiol Ther. 2022 Jun;11(2):203-230. doi: 10.1007/s40119-022-00260-y. Epub 2022 Mar 30. Cardiol Ther. 2022. PMID: 35353354 Free PMC article. Review.
-
The structural OFF and ON states of myosin can be decoupled from the biochemical super-relaxed and disordered-relaxed states.bioRxiv [Preprint]. 2023 Oct 20:2023.10.18.562891. doi: 10.1101/2023.10.18.562891. bioRxiv. 2023. Update in: PNAS Nexus. 2024 Jan 30;3(2):pgae039. doi: 10.1093/pnasnexus/pgae039. PMID: 37904972 Free PMC article. Updated. Preprint.
-
The Super-Relaxed State and Length Dependent Activation in Porcine Myocardium.Circ Res. 2021 Sep 3;129(6):617-630. doi: 10.1161/CIRCRESAHA.120.318647. Epub 2021 Aug 9. Circ Res. 2021. PMID: 34365814 Free PMC article.
-
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022.Eur Heart J Cardiovasc Pharmacother. 2023 May 11;9(4):353-70. doi: 10.1093/ehjcvp/pvad034. Online ahead of print. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 37169875 Free PMC article.
References
-
- Adhikari AS, Trivedi DV, Sarkar SS, Song D, Kooiker KB, Bernstein D, Spudich JA, Ruppel KM (2019) Hypertrophic cardiomyopathy mutations at the folded-back sequestered β-cardiac myosin S1-S2 and S1-S1 interfaces release sequestered heads and increase myosin enzymatic activity. BioRxiv. 10.1101/537159 - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources